View in EDS

Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?

Saved in:
Bibliographic Details
Title: Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?
Authors: Zhao Y; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom., Gallon J; Tagomics, Cambridge, United Kingdom., Kushner MH; External R&D, Oncology R&D, AstraZeneca, Gaithersburg, MD., Jakubison B; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD., Reis-Filho JS; Data Science & AI, AstraZeneca, Gaithersburg, MD., Hodgson D; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom., Elvin J; Cancer Biomarker Development, AstraZeneca, Waltham, MA., Dor Y; Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel., Hadfield J; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom.
Source: JCO precision oncology [JCO Precis Oncol] 2026 May; Vol. 10 (5), pp. e2600178. Date of Electronic Publication: 2026 May 21.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42163707
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhao+Y%22">Zhao Y</searchLink>; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gallon+J%22">Gallon J</searchLink>; Tagomics, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kushner+MH%22">Kushner MH</searchLink>; External R&D, Oncology R&D, AstraZeneca, Gaithersburg, MD.<br /><searchLink fieldCode="AU" term="%22Jakubison+B%22">Jakubison B</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD.<br /><searchLink fieldCode="AU" term="%22Reis-Filho+JS%22">Reis-Filho JS</searchLink>; Data Science & AI, AstraZeneca, Gaithersburg, MD.<br /><searchLink fieldCode="AU" term="%22Hodgson+D%22">Hodgson D</searchLink>; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Elvin+J%22">Elvin J</searchLink>; Cancer Biomarker Development, AstraZeneca, Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Dor+Y%22">Dor Y</searchLink>; Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Hadfield+J%22">Hadfield J</searchLink>; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2026 May; Vol. 10 (5), pp. e2600178. <i>Date of Electronic Publication: </i>2026 May 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42163707
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/PO-26-00178
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e2600178
    Titles:
      – TitleFull: Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhao Y
      – PersonEntity:
          Name:
            NameFull: Gallon J
      – PersonEntity:
          Name:
            NameFull: Kushner MH
      – PersonEntity:
          Name:
            NameFull: Jakubison B
      – PersonEntity:
          Name:
            NameFull: Reis-Filho JS
      – PersonEntity:
          Name:
            NameFull: Hodgson D
      – PersonEntity:
          Name:
            NameFull: Elvin J
      – PersonEntity:
          Name:
            NameFull: Dor Y
      – PersonEntity:
          Name:
            NameFull: Hadfield J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2473-4284
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: JCO precision oncology
              Type: main
ResultId 1